Atlas Trials

Study of Ixazomib to Prevent Recurrent or Late Acute and Chronic Graft-versus-Host Disease 1-year After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Malignancies

Clinical trial NCT03082677 · COMPLETED

Trial details

NCT number
NCT03082677
Sponsor
Memorial Sloan Kettering Cancer Center
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Myeloid Hematologic MalignancyLymphoid Hematologic Malignancy
Start date
2017-03-10
Primary completion
2021-09-02
Enrollment
20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.